VANCOUVER, Washington, Nov. 12, 2026 (GLOBE NEWSWIRE) --

华盛顿州温哥华，2026年11月12日（环球社）--

CytoDyn Inc. (OTCQB: CYDY)

CytoDyn Inc.（OTCQB: CYDY）

('CytoDyn' or the 'Company'), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced that a private investor has made an additional $5 million investment into the Company in support of its clinical development of leronlimab..

CytoDyn（以下简称“公司”）是一家处于临床阶段的肿瘤学公司，正在推进leronlimab的研发。Leronlimab是一种首创的人源化单克隆抗体，靶向CCR5受体，在包括结直肠癌（CRC）和三阴性乳腺癌（TNBC）在内的多种适应症中具有治疗潜力。该公司今日宣布，一位私人投资者已向公司追加投资500万美元，以支持leronlimab的临床开发。

The investor, who wishes to remain anonymous at this time, has previously invested in the Company and has a longstanding interest in advancing innovative cancer therapies and improving patient access to promising treatment approaches. The investment was completed at a purchase price of $0.24 per common share, with no accompanying warrants, resulting in total proceeds of $5 million.

该投资者目前希望保持匿名，此前曾对本公司进行投资，并长期致力于推动创新癌症疗法的发展以及改善患者获得前景良好的治疗方案的渠道。此次投资以每股普通股0.24美元的价格完成，不附带任何认股权证，总募资额为500万美元。

The proceeds will support further development of the Company's colorectal cancer program, building on emerging findings from its CLOVER study, while also furthering the exploration of leronlimab in earlier lines of treatment and other oncology indications, including TNBC, pancreatic cancer and glioblastoma..

所得款项将用于支持公司结直肠癌项目的进一步开发，基于其CLOVER研究中涌现的最新发现，同时推进对leronlimab在更早线治疗及其他肿瘤适应症（包括三阴性乳腺癌、胰腺癌和胶质母细胞瘤）中的探索。

“We are grateful for this investor’s continued confidence in leronlimab and commitment to supporting the development of new treatment options for patients with cancer,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “We believe this investment reflects support for CytoDyn’s recent data, as well as the emerging scientific and clinical evidence supporting leronlimab's therapeutic potential across multiple solid-tumor indications.

“我们感谢这位投资者对leronlimab的持续信心，以及其致力于支持为癌症患者开发新治疗方案的承诺，”CytoDyn首席执行官Robert E. Hoffman表示。“我们认为，这项投资反映了市场对CytoDyn近期数据的支持，也体现了新兴的科学和临床证据对leronlimab在多种实体瘤适应症中治疗潜力的认可。”

The investment comes at an important time as we continue to build on emerging clinical findings and advance the development of leronlimab across multiple solid tumors. This support will help us advance our clinical and translational research efforts as we continue to generate the evidence needed to inform future regulatory pathways.”.

此次投资时机至关重要，因为我们正基于新兴的临床发现，持续推进leronlimab在多种实体瘤中的开发。这一支持将有助于我们推进临床与转化研究工作，继续生成为未来监管路径提供依据所需的证据。

About CytoDyn

关于 CytoDyn

CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide..

CytoDyn 是一家处于临床阶段的肿瘤学公司，致力于推进 leronlimab 的研发。Leronlimab 是一种首创的人源化单克隆抗体，靶向 CCR5 受体；CCR5 受体是免疫功能的关键调节因子，与癌症、传染病和自身免疫性疾病密切相关。在以通过治疗创新改善患者生活质量为使命的指引下，CytoDyn 秉持诚信、责任和服务的理念，致力于为全球患者带来变革性的治疗方案。

For more information, please visit

更多信息，请访问

www.cytodyn.com

www.cytodyn.com

and follow us on

并在关注我们

LinkedIn

领英

.

。

Note Regarding Forward-Looking Statements

关于前瞻性陈述的说明

This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events.

本新闻稿可能包含涉及作用机制、临床开发计划、临床试验结果、产品开发、市场地位、未来经营和财务表现以及业务战略等方面的前瞻性陈述。提醒读者不要依赖这些基于对未来事件当前预期的陈述。

For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission.

有关这些陈述及本公司的重要信息，包括可能导致实际结果与任何前瞻性陈述中表达的假设、预期和预测产生重大差异的风险、不确定性及其他因素，读者应查阅我们截至2026年5月31日止财政年度的10-K表格年度报告，特别是其中题为“前瞻性陈述”的章节以及第1A项，并参阅随后向美国证券交易委员会提交的报告。

CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law..

CytoDyn Inc. 不承担因新信息或未来事件或发展而更新任何前瞻性声明的义务，除非适用法律另有要求。

Corporate Contact

企业联系方式

CytoDyn Inc.

CytoDyn 公司

ir@cytodyn.com

ir@cytodyn.com

Media Contacts

媒体联系人

David Schull or Ignacio Guerrero-Ros, Ph.D.

David Schull 或 Ignacio Guerrero-Ros，博士

Russo Partners, LLC

Russo Partners, LLC

CytoDyn@russopartnersllc.com

CytoDyn@russopartnersllc.com